S-nitrosoglutathione reductase and airways hyperreactivity in murine bronchopulmonary dysplasia
S-nitrosoglutathione reductase and airways hyperreactivity in murine bronchopulmonary dysplasia
批准号:
9975210
负责人:
Thomas Michael Raffay
金额:
$16.42万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-14 至 2022-06-30
关键词:
AcuteAdolescentAdultAerosolsAgonistAirAirway DiseaseAlveolarAnimal ModelAnti-Inflammatory AgentsAsthmaAttenuatedBiologyBreathingBronchial SpasmBronchoconstrictionBronchodilator AgentsBronchopulmonary DysplasiaCatabolismCell SeparationCellsChildChildhoodChronicClinicClinicalClinical TrialsComplicationCystic FibrosisDataDevelopmentDiagnosisDoseDown-RegulationEducational process of instructingEnzymesExposure toExtramural ActivitiesExtrinsic asthmaFlow CytometryFluorescence-Activated Cell SortingGasesHumanHyperoxiaIncidenceInfantInhalationInternationalKnock-outKnockout MiceLeadLifeLocationLoxP-flanked alleleLungLung diseasesMeasuresMentorsMentorshipMicroRNAsModelingMusNeonatalNeonatal Hyperoxic InjuryNewborn InfantOxidoreductaseOxygenPediatric HospitalsPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhenotypePremature BirthPremature InfantPropertyResearchResearch PersonnelResearch TrainingS-NitrosoglutathioneS-NitrosothiolsScientistSeveritiesSignal TransductionSiteSmooth MuscleStructureStructure of parenchyma of lungSupplementationSurvivorsTestingTimeTissuesTrainingTransgenic AnimalsTransgenic MiceTranslational ResearchUnited StatesUniversitiesWheezingWild Type Mouseaerosolizedairway hyperresponsivenessairway obstructionattenuationbasecareer developmentconditional knockoutcostenzyme activityexperiencefetalimprovedinhibitor/antagonistlaboratory experiencemouse modelnoveloverexpressionpreventprotein expressionpuprespiratoryrespiratory smooth musclescaffoldskills trainingsocioeconomics
中文摘要
项目摘要/总结:
该提案描述了一个五年期指导研究和培训计划,
托马斯拉菲博士,医学博士的新生儿肺部疾病的独立调查。建筑在博士。
Raffay的背景是临床呼吸科医生和气道反应性和新生儿呼吸系统疾病的基础科学家。
支气管肺发育不良(BPD),他将获得S-亚硝基硫醇生物学,流式细胞术,条件
转基因动物模型,药理学和转化科学,通过结构化的指导,严格的
在凯斯西方的实践实验室经验,教学法教学,正式的课堂作业和技能培训
储备大学/彩虹婴儿和儿童医院,马约诊所罗切斯特,和大学
温莎。Benjamin Gaston博士是儿科肺病中S-亚硝基硫醇信号传导的先驱,Richard J
马丁,在新生儿气道疾病和BPD的国际领导者,将提供他们的专业知识和
建立了对该项目的指导记录以及Raffay博士向独立研究的过渡。在
在美国,每年有14,000例儿童肺病BPD的新诊断,
早产儿,费用超过25亿美元。治疗选择是有限的严重
支气管痉挛和终身气道阻塞的特征BPD。使用新生高氧小鼠
根据BPD和气道高反应性模型,Raffay博士的新数据确定了一种可行的治疗方法。的治疗
S-亚硝基谷胱甘肽(GSNO)单次气雾剂逆转幼年BPD小鼠气道高反应性
和室内空气恢复成人。GSNO是一种有效的内源性支气管扩张剂,对气道疾病至关重要
哮喘和囊性纤维化在这个模型中,新生儿高氧增加了GSNO的分解代谢
由酶S-亚硝基谷胱甘肽还原酶(GSNOR)的表达和活性增加引起,至少
部分通过高氧下调microRNA(miR-342- 3 p)。这项研究将测试整体
假设GSNOR活性丧失或抑制将防止青少年BPD气道高反应性
成年老鼠本研究旨在探讨新生儿高氧对BPD气道高反应性的影响
利用GSNOR基因敲除小鼠(Aim 1A)进行肺实质重塑;鉴定肺组织
参与GSNOR和miR-342- 3 p表达,利用荧光激活细胞分选和开发,
测试条件性GSNOR敲除小鼠(Aim 1B);在野生型小鼠中测试药物级GSNOR抑制剂药物,
型小鼠缓解急性支气管收缩(Aim 2a)和慢性减弱BPD表型(Aim
2b)。在翻译人类目标(目标3)中:GSNOR水平,实时荧光GSNO催化剂,和
将在暴露于高氧的人胎儿气道平滑肌中测量微小RNA表达;以及
将测试GSNO和GSNOR抑制剂作为用于减弱氧诱导的高血压的治疗。
收缩性这些研究在临床上很重要,因为GSNOR抑制剂目前正在进行临床试验,
囊性纤维化和哮喘,最终可以作为一种新的治疗支气管肺发育不良。
英文摘要
Project Abstract/Summary:
This proposal describes a five-year mentored research and training plan that will facilitate the development
of Dr. Thomas Raffay, MD to an independent investigator in neonatal pulmonary disease. Building upon Dr.
Raffay's background as a clinical neonatologist and a basic scientist in airways reactivity and neonatal
bronchopulmonary dysplasia (BPD), he will attain expertise in S-nitrosothiol biology, flow-cytometry, conditional
transgenic animal models, pharmacology, and translational science through structured mentorship, rigorous
hands-on laboratory experiences, didactics teaching, and formal classwork and skills training at Case Western
Reserve University/Rainbow Babies and Children's Hospital, the Mayo Clinic Rochester, and the University of
Windsor. Dr. Benjamin Gaston, a pioneer in S-nitrosothiol signaling in pediatric lung disease, and Dr. Richard J
Martin, an international leader in neonatal airways disease and BPD, will provide their expertise and an
established track record of mentorship to this project and Dr. Raffay's transition to research independence. In
the United States, 14,000 new diagnoses of the pediatric lung disease, BPD, are made annually in surviving
premature infants, with costs exceeding $2.5 billion. Treatment options are limited for the severe
bronchospasms and life-long airway obstruction that characterize BPD. Using a neonatal hyperoxia mouse
model of BPD and airways hyperreactivity, Dr. Raffay's new data identify a viable therapy. Treatment with a
single aerosol of S-nitrosoglutathione (GSNO) reverses airways hyperresponsiveness in juvenile BPD mice
and room air recovered adults. GSNO is a potent endogenous bronchodilator, critical for the airways diseases
of asthma and cystic fibrosis. In this model, neonatal hyperoxia increases the catabolic breakdown of GSNO
caused by increased expression and activity of the enzyme, S-nitrosoglutathione reductase (GSNOR), at least
in part through hyperoxic downregulation of a microRNA (miR-342-3p). This study will test the overall
hypothesis that loss or inhibition of GSNOR activity will protect against BPD airways hyperreactivity in juvenile
and adult mice. This proposal will evaluate the effects of neonatal hyperoxia on BPD airways hyperreactivity
and parenchymal lung remodeling utilizing global GSNOR knockout mice (Aim 1A); identify the lung tissues
involved in GSNOR and miR-342-3p expression utilizing fluorescence-activated cell sorting and develop and
test conditional GSNOR knockout mice (Aim 1B); test a pharmaceutical-grade GSNOR inhibitor drug in wild-
type mice to alleviate acute bronchoconstriction (Aim 2a) and chronically to attenuate the BPD phenotype (Aim
2b). In a translational human aim (Aim 3): GSNOR levels, real-time fluorescent GSNO catabolism, and
microRNA expression will be measured in human fetal airway smooth muscle exposed to hyperoxia; and
GSNO and GSNOR inhibitors will be tested as a treatment for attenuation of oxygen induced hyper-
contractility. These studies are clinically important because GSNOR inhibitors are currently in clinical trials for
cystic fibrosis and asthma which could ultimately serve as a new treatment for bronchopulmonary dysplasia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pilot Study of an Inhaled Treatment for Bronchopulmonary Dysplasia
-
批准号:10455406
-
项目类别:
-
资助金额:$6.82万
-
财政年份:2021
-
负责人:Thomas Michael Raffay
-
依托单位:
S-nitrosoglutathione reductase and airways hyperreactivity in murine bronchopulmonary dysplasia
-
批准号:9386538
-
项目类别:
-
资助金额:$16.47万
-
财政年份:2017
-
负责人:Thomas Michael Raffay
-
依托单位:
S-nitrosoglutathione reductase and airways hyperreactivity in murine bronchopulmonary dysplasia
-
批准号:10208930
-
项目类别:
-
资助金额:$16.36万
-
财政年份:2017
-
负责人:Thomas Michael Raffay
-
依托单位:
海外基金